Equities Analysts Issue Forecasts for ARWR Q2 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Research analysts at HC Wainwright lowered their Q2 2026 EPS estimates for Arrowhead Pharmaceuticals in a report released on Tuesday, February 10th. HC Wainwright analyst P. Trucchio now expects that the biotechnology company will post earnings per share of ($0.98) for the quarter, down from their previous forecast of ($0.97). HC Wainwright has a “Buy” rating and a $100.00 price target on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ Q3 2026 earnings at ($1.02) EPS, Q4 2026 earnings at ($1.03) EPS, FY2026 earnings at ($2.83) EPS, Q1 2027 earnings at ($1.03) EPS, Q2 2027 earnings at ($1.24) EPS, Q3 2027 earnings at ($1.25) EPS, Q4 2027 earnings at $0.13 EPS, FY2027 earnings at ($3.36) EPS, FY2028 earnings at ($3.16) EPS, FY2029 earnings at ($1.05) EPS and FY2030 earnings at $3.08 EPS.

ARWR has been the subject of a number of other reports. Royal Bank Of Canada lifted their price target on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a report on Thursday, December 11th. Bank of America boosted their target price on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Morgan Stanley upped their price target on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the company an “equal weight” rating in a report on Wednesday, January 7th. B. Riley Financial raised their price objective on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. Finally, Piper Sandler restated an “overweight” rating and issued a $110.00 target price (up previously from $100.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, January 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $81.67.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR stock opened at $61.55 on Thursday. The company has a market cap of $8.62 billion, a P/E ratio of 40.23 and a beta of 1.21. The firm has a fifty day moving average price of $67.02 and a 200 day moving average price of $44.60. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.29. Arrowhead Pharmaceuticals has a 12 month low of $9.57 and a 12 month high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 EPS for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). The firm had revenue of $264.03 million during the quarter, compared to analysts’ expectations of $225.66 million. Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The company’s revenue for the quarter was up 10461.3% on a year-over-year basis. During the same period in the prior year, the company posted ($1.39) earnings per share.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in Arrowhead Pharmaceuticals by 3.3% during the third quarter. Vanguard Group Inc. now owns 16,035,870 shares of the biotechnology company’s stock worth $553,077,000 after purchasing an additional 510,798 shares in the last quarter. Avoro Capital Advisors LLC increased its position in Arrowhead Pharmaceuticals by 2.8% during the 3rd quarter. Avoro Capital Advisors LLC now owns 10,900,000 shares of the biotechnology company’s stock worth $375,941,000 after purchasing an additional 300,000 shares during the period. Geode Capital Management LLC raised its stake in shares of Arrowhead Pharmaceuticals by 4.3% during the 4th quarter. Geode Capital Management LLC now owns 3,264,963 shares of the biotechnology company’s stock worth $216,799,000 after buying an additional 133,921 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of Arrowhead Pharmaceuticals by 3,507.8% in the 2nd quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after buying an additional 2,096,238 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its stake in shares of Arrowhead Pharmaceuticals by 3,142.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock valued at $71,797,000 after buying an additional 2,017,489 shares in the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Adeoye Y. Olukotun sold 10,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Friday, December 19th. The shares were sold at an average price of $67.66, for a total value of $676,600.00. Following the transaction, the director directly owned 33,600 shares of the company’s stock, valued at $2,273,376. The trade was a 22.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider James C. Hamilton sold 40,164 shares of the stock in a transaction on Monday, January 5th. The stock was sold at an average price of $63.11, for a total transaction of $2,534,750.04. Following the sale, the insider owned 171,958 shares of the company’s stock, valued at approximately $10,852,269.38. This represents a 18.93% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 510,836 shares of company stock valued at $33,603,060 in the last 90 days. Company insiders own 3.60% of the company’s stock.

Key Arrowhead Pharmaceuticals News

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reaffirmed a Buy rating and a $100 price target on ARWR, reiterating bullish conviction (the target implies substantial upside vs. the current level). HC Wainwright Reaffirms Buy Rating for Arrowhead Pharmaceuticals
• Positive Sentiment: The same HC Wainwright note raised several medium‑ and long‑range EPS forecasts (examples: Q4 2027 moved to +$0.13; FY2027, FY2028 and FY2030 were nudged toward less negative or positive territory, FY2030 to $3.08), implying a constructive multi‑year revenue/profit trajectory that supports the $100 target. MarketBeat ARWR analyst updates
• Positive Sentiment: HC Wainwright also upgraded several quarterly estimates (e.g., Q3 and Q4 2026 and Q3 2027 were revised higher), which reduces near‑term downside in their model and reflects improving operating momentum in projected quarters. MarketBeat ARWR analyst updates
• Neutral Sentiment: Company product update: coverage notes point to a “strong start” for REDEMPLO commercialization (early revenue signal that could validate forecasts if sustained). This is encouraging but preliminary—monitor upcoming sales cadence and guidance for impact. ARWR: Strong Start for REDEMPLO Commercialization
• Neutral Sentiment: Reported short‑interest entries show zero shares/0 days-to-cover in the feed (likely a data artifact). That reading does not provide reliable evidence of crowd positioning; treat as neutral until clearer reporting.
• Negative Sentiment: Offsetting the positives, HC Wainwright trimmed FY2026 EPS significantly (to -$2.83 from -$2.03) and lowered a few near‑term quarterly forecasts (Q1/Q2 2027 nudged down), which implies a weaker near‑term profit profile than previously modeled and may pressure the stock while investors re‑assess short‑term guidance. MarketBeat ARWR analyst updates

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.